<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39323444</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2220-3249</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>25</Day></PubDate></JournalIssue><Title>World journal of virology</Title><ISOAbbreviation>World J Virol</ISOAbbreviation></Journal><ArticleTitle>Dosage and utilization of dexamethasone in the management of COVID-19: A critical review.</ArticleTitle><Pagination><StartPage>95709</StartPage><MedlinePgn>95709</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">95709</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.5501/wjv.v13.i3.95709</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The severe respiratory manifestations observed in severe coronavirus disease 2019 (COVID-19) cases are often associated with an excessive inflammatory response. Dexamethasone, a synthetic glucocorticoid, exerts its anti-inflammatory effects by inhibiting the transcription of pro-inflammatory genes and suppressing the activity of various immune cells. This mechanism has implications for mitigating the cytokine storm observed in severe COVID-19 cases. Early on in the pandemic, the Recovery Collaborative working group showed a mortality benefit of using dexamethasone in decreasing mortality in patients with COVID-19 requiring respiratory support. However, the optimal dosage of corticosteroids remains debatable. Several studies that compare different doses of dexamethasone in COVID-19 exist, but the results are conflicting.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To review the latest evidence regarding dosage, safety, and efficacy of dexamethasone in severe COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We followed preferred reporting items for systematic reviews and meta-analysis guidelines. A detailed literature search was conducted across PubMed, Google Scholar, and Medline to include publications up to March 2024. Our keywords included "COVID-19" "SARS-CoV-2" "dexamethasone" "corticosteroid" "steroid" and "glucocorticoid"-along with their combinations. We employed the Cochrane Risk of Bias Tool and the Newcastle-Ottawa scale to evaluate the integrity and potential of bias in the included studies. A meta-analysis was conducted using a random-effects model, assessing pooled odds ratios and mean differences, with heterogeneity gauged by the <i>I</i> <sup>2</sup> statistic and the <i>χ</i> <sup>2</sup> tests.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">No statistical differences were found in 28-day all-cause mortality [pooled odds ratio (OR) = 1.109, 95%CI: 0.918-1.340], 60-day all-cause mortality (OR = 0.873, 95%CI: 0.744-1.024; <i>I</i> <sup>2</sup> = 47.29%), mean length of hospital stay (mean difference = -0.08 days, 95%CI: -0.001 to 0.161) and adverse events (OR = 0.877, 95%CI: 0.707-1.087).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Differing doses of corticosteroids have no clinical implications on mortality, mean length of hospital stay, and adverse events in COVID-19 patients. Additional research is required in patients requiring invasive or non-invasive ventilation.</AbstractText><CopyrightInformation>©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sethi</LastName><ForeName>Imran</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Marion General Hospital, Marion, IN 46952, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaikh</LastName><ForeName>Asim</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Aga Khan University, Karachi 74200, Sindh, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sethi</LastName><ForeName>Musa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, Eman School, Fishers, IN 46038, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chohan</LastName><ForeName>Hira Khalid</ForeName><Initials>HK</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Dow University of Health Science, Karachi 74200, Sindh, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Younus</LastName><ForeName>Sheraz</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Hospital Medicine, Franciscan Health, Indianapolis, IN 46237, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Syed A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Mayo Clinic Health System, Mankato, MN 56001, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Surani</LastName><ForeName>Salim</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine and Pharmacology, Texas A and M University, College Station, TX 77843, United States. srsurani@hotmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>World J Virol</MedlineTA><NlmUniqueID>101608353</NlmUniqueID><ISSNLinking>2220-3249</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Corona virus</Keyword><Keyword MajorTopicYN="N">Corticosteroids</Keyword><Keyword MajorTopicYN="N">Critical care</Keyword><Keyword MajorTopicYN="N">Steroid dosage</Keyword><Keyword MajorTopicYN="N">Steroids</Keyword></KeywordList><CoiStatement>Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>11</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>11</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>4</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39323444</ArticleId><ArticleId IdType="pmc">PMC11401006</ArticleId><ArticleId IdType="doi">10.5501/wjv.v13.i3.95709</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ Recovery Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384:693–704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Safe IP, Lacerda MVG, Almeida Val FF, Sampaio VS, Hajjar LA, Brito-Sousa JD, Baía-da-Silva D, Bassat Q, Landoni G, Monteiro WM. Severe Hypoxemia With Normal Heart and Respiratory Rate in Early-stage Coronavirus Disease 2019 Patients: The "Happy Hypoxemia Phenomenon". Clin Infect Dis. 2021;73:e856–e858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7953969</ArticleId><ArticleId IdType="pubmed">33624795</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleishaker DL, Mukherjee A, Whaley FS, Daniel S, Zeiher BG. Safety and pharmacodynamic dose response of short-term prednisone in healthy adult subjects: a dose ranging, randomized, placebo-controlled, crossover study. BMC Musculoskelet Disord. 2016;17:293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4947329</ArticleId><ArticleId IdType="pubmed">27424036</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Wang H, Li S, Liu J, Qiao L. A systematic review and meta-analysis of glucocorticoids treatment in severe COVID-19: methylprednisolone versus dexamethasone. BMC Infect Dis. 2023;23:290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10162003</ArticleId><ArticleId IdType="pubmed">37147596</ArticleId></ArticleIdList></Reference><Reference><Citation>Munch MW, Myatra SN, Vijayaraghavan BKT, Saseedharan S, Benfield T, Wahlin RR, Rasmussen BS, Andreasen AS, Poulsen LM, Cioccari L, Khan MS, Kapadia F, Divatia JV, Brøchner AC, Bestle MH, Helleberg M, Michelsen J, Padmanaban A, Bose N, Møller A, Borawake K, Kristiansen KT, Shukla U, Chew MS, Dixit S, Ulrik CS, Amin PR, Chawla R, Wamberg CA, Shah MS, Darfelt IS, Jørgensen VL, Smitt M, Granholm A, Kjær MN, Møller MH, Meyhoff TS, Vesterlund GK, Hammond NE, Micallef S, Bassi A, John O, Jha A, Cronhjort M, Jakob SM, Gluud C, Lange T, Kadam V, Marcussen KV, Hollenberg J, Hedman A, Nielsen H, Schjørring OL, Jensen MQ, Leistner JW, Jonassen TB, Kristensen CM, Clapp EC, Hjortsø CJS, Jensen TS, Halstad LS, Bak ERB, Zaabalawi R, Metcalf-Clausen M, Abdi S, Hatley EV, Aksnes TS, Gleipner-Andersen E, Alarcón AF, Yamin G, Heymowski A, Berggren A, La Cour K, Weihe S, Pind AH, Engstrøm J, Jha V, Venkatesh B, Perner A COVID Steroid 2 Trial Group. Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial. JAMA. 2021;326:1807–1817.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8532039</ArticleId><ArticleId IdType="pubmed">34673895</ArticleId></ArticleIdList></Reference><Reference><Citation>Maskin LP, Bonelli I, Olarte GL, Palizas F Jr, Velo AE, Lurbet MF, Lovazzano P, Kotsias S, Attie S, Lopez Saubidet I, Baredes ND, Setten M, Rodriguez PO. High- Versus Low-Dose Dexamethasone for the Treatment of COVID-19-Related Acute Respiratory Distress Syndrome: A Multicenter, Randomized Open-Label Clinical Trial. J Intensive Care Med. 2022;37:491–499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8926919</ArticleId><ArticleId IdType="pubmed">34898320</ArticleId></ArticleIdList></Reference><Reference><Citation>Recovery Collaborative Group. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2023;401:1499–1507.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10156147</ArticleId><ArticleId IdType="pubmed">37060915</ArticleId></ArticleIdList></Reference><Reference><Citation>Toroghi N, Abbasian L, Nourian A, Davoudi-Monfared E, Khalili H, Hasannezhad M, Ghiasvand F, Jafari S, Emadi-Kouchak H, Yekaninejad MS. Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial. Pharmacol Rep. 2022;74:229–240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8627167</ArticleId><ArticleId IdType="pubmed">34837648</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H, Daouk S, Kebbe J, Chaudry F, Harper J, Brown B. Low-dose versus high-dose dexamethasone for hospitalized patients with COVID-19 pneumonia: A randomized clinical trial. PLoS One. 2022;17:e0275217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9529091</ArticleId><ArticleId IdType="pubmed">36190994</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Taboada M, Rodríguez N, Varela PM, Rodríguez MT, Abelleira R, González A, Casal A, Díaz Peromingo JA, Lama A, Domínguez MJ, Rábade C, Páez EM, Riveiro V, Pernas H, Beceiro MDC, Caruezo V, Naveira A, Cariñena A, Cabaleiro T, Estany-Gestal A, Zarra I, Pose A, Valdés L, Álvarez-Escudero J. Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial. Eur Respir J. 2022;60</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8678498</ArticleId><ArticleId IdType="pubmed">34916266</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouadma L, Mekontso-Dessap A, Burdet C, Merdji H, Poissy J, Dupuis C, Guitton C, Schwebel C, Cohen Y, Bruel C, Marzouk M, Geri G, Cerf C, Mégarbane B, Garçon P, Kipnis E, Visseaux B, Beldjoudi N, Chevret S, Timsit JF COVIDICUS Study Group. High-Dose Dexamethasone and Oxygen Support Strategies in Intensive Care Unit Patients With Severe COVID-19 Acute Hypoxemic Respiratory Failure: The COVIDICUS Randomized Clinical Trial. JAMA Intern Med. 2022;182:906–916.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9449796</ArticleId><ArticleId IdType="pubmed">35788622</ArticleId></ArticleIdList></Reference><Reference><Citation>Granholm A, Kjær MN, Munch MW, Myatra SN, Vijayaraghavan BKT, Cronhjort M, Wahlin RR, Jakob SM, Cioccari L, Vesterlund GK, Meyhoff TS, Helleberg M, Møller MH, Benfield T, Venkatesh B, Hammond NE, Micallef S, Bassi A, John O, Jha V, Kristiansen KT, Ulrik CS, Jørgensen VL, Smitt M, Bestle MH, Andreasen AS, Poulsen LM, Rasmussen BS, Brøchner AC, Strøm T, Møller A, Khan MS, Padmanaban A, Divatia JV, Saseedharan S, Borawake K, Kapadia F, Dixit S, Chawla R, Shukla U, Amin P, Chew MS, Wamberg CA, Bose N, Shah MS, Darfelt IS, Gluud C, Lange T, Perner A. Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia. Intensive Care Med. 2022;48:580–589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8970069</ArticleId><ArticleId IdType="pubmed">35359168</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabascall CX, Lou BX, Dhar S, Hasan Z, Fryman C, Izard S, Makaryus M, Acharya S, Mastroianni F, Kamper M, Duenas S, Gong J, Shah D, Khanijo S, Ying D, Habibullah J, Kim DH, Butzko R, Oks M, Birnbaum B, Moore J, Singh AK, Quintero L, Lau M, Honigman J, Hilewitz A, Shah K, Simonson J, Agrawal A, Frank M, Tsegaye A, Narasimhan M, Greenberg H, Hahn SS. Randomized Open Investigation Determining Steroid Dose in Severe COVID-19: The ROIDS-Dose Clinical Trial. Cureus. 2022;14:e31086.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9720033</ArticleId><ArticleId IdType="pubmed">36475114</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghi S, Arezoomandi N, Ardestani MM, Ardestani ME, Ghiasi F, Farajzadegan Z. Efficacy and Safety Comparison of Two Different Doses of Dexamethasone in Hospitalized Patients with COVID-19: A Randomized Clinical Trial. J Res Pharm Pract. 2022;11:136–143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10642588</ArticleId><ArticleId IdType="pubmed">37969616</ArticleId></ArticleIdList></Reference><Reference><Citation>Piscoya A, Parra Del Riego A, Cerna-Viacava R, Rocco J, Roman YM, Escobedo AA, Pasupuleti V, White CM, Hernandez AV. Efficacy and harms of tocilizumab for the treatment of COVID-19 patients: A systematic review and meta-analysis. PLoS One. 2022;17:e0269368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9165853</ArticleId><ArticleId IdType="pubmed">35657993</ArticleId></ArticleIdList></Reference><Reference><Citation>Monreal E, Sainz de la Maza S, Natera-Villalba E, Beltrán-Corbellini Á, Rodríguez-Jorge F, Fernández-Velasco JI, Walo-Delgado P, Muriel A, Zamora J, Alonso-Canovas A, Fortún J, Manzano L, Montero-Errasquín B, Costa-Frossard L, Masjuan J, Villar LM COVID-HRC group. High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study. Eur J Clin Microbiol Infect Dis. 2021;40:761–769.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7575217</ArticleId><ArticleId IdType="pubmed">33083917</ArticleId></ArticleIdList></Reference><Reference><Citation>Okano H, Sakurai R, Yamazaki T. Steroid Pulse Therapy as a Treatment for Patients With COVID-19 Pneumonia at an Intensive Care Unit: A Single-Center Retrospective Observational Study. Cureus. 2023;15:e36386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10025871</ArticleId><ArticleId IdType="pubmed">36945235</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi KJ, Jung SK, Kim KC, Kim EJ. Methylprednisolone pulse therapy for critically ill patients with COVID-19: a cohort study. Acute Crit Care. 2023;38:57–67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10030243</ArticleId><ArticleId IdType="pubmed">36935535</ArticleId></ArticleIdList></Reference><Reference><Citation>Odeyemi YE, Chalmers SJ, Barreto EF, Jentzer JC, Gajic O, Yadav H. Early, biomarker-guided steroid dosing in COVID-19 Pneumonia: a pilot randomized controlled trial. Crit Care. 2022;26:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8724733</ArticleId><ArticleId IdType="pubmed">34983600</ArticleId></ArticleIdList></Reference><Reference><Citation>Tekin A, Domecq JP, Valencia Morales DJ, Surapeneni KM, Zabolotskikh IB, Cartin-Ceba R, Clevenbergh P, Mesland JB, Claure-Del Granado R, Gavidia OY, Kumar VK, Kashyap R, Walkey AJ, Gajic O, Odeyemi Y From the Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry Investigator Group. Biomarker-Concordant Steroid Administration in Severe Coronavirus Disease-2019. J Intensive Care Med. 2023;38:1003–1014.</Citation><ArticleIdList><ArticleId IdType="pubmed">37226483</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>